Improvement in Parkinson Disease Symptoms After Treatment for COVID-19 with Monoclonal Antibodies.

Background: Parkinson disease (PD) is a neurodegenerative disease characterized by motor symptoms, such as bradykinesia, and non-motor symptoms, such as fatigue, which can be a particularly disabling feature of the disease.

Methods: We conducted a retrospective chart review on a patient who reported improvement in baseline PD symptoms after COVID-19 treatment.

Results: The patient is a 76-year-old male with a six-year history of PD who developed a COVID-19 infection, underwent treatment with COVID-19 monoclonal antibodies, and experienced a remarkable improvement in his pre-COVID PD symptoms, most notably his gait and fatigue. Prior to COVID, he rated his fatigue as '9 out of 10,' which worsened to 10 out of 10 during his COVID infection, and post-COVID treatment, his fatigue improved to '3 out of 10'.

Principal Conclusions: We described an unexpected improvement in baseline PD symptoms for a patient treated with COVID-19 monoclonal antibodies. Further investigation will be essential to understand the mechanisms underlying this phenomenon.